TNFSF10 and cancer: However, the co-treatment of PC3 cancer cells with TRAIL at the concentration of 100 ng/mL and paclitaxel at the concentrations of 0.25 μM and 0.5 μM decreased the percentage of CSCs, respectively, to 6.3% ± 0.7% and 6.2% ± 0.7%.